Discussion  by unknown
as a result of a non–cancer-related cause. Thus concerns re-
garding the significantly increased age and comorbidities in
the transhiatal group affecting survival are unfounded, and
an analysis of only cancer-related deaths merely strengthens
the significance of our findings. Another issue is that we de-
liberately did not provide preoperative staging information
because clinical staging for esophageal cancer is poor. How-
ever, our bias is to perform primary en bloc resection in
patients with limited local-regional disease. Patients with lo-
cally advanced tumors with multiple nodes on endoscopic
ultrasonographic analysis or PET scanning are referred for
neoadjuvant therapy, and the decision for an en bloc versus
transhiatal resection after neoadjuvant therapy is not based
on response but is made purely on the basis of the age, comor-
bid conditions, and cardiopulmonary status of the patient. If
anything, in this study the deck was stacked against the en
bloc group, where follow-up was longest, fewer patients
had a complete pathologic response, and 68% had stage 2
or 3 disease compared with 44% in the transhiatal group after
therapy. Thus the survival differences we demonstrated are
unlikely to be due to substantial differences in preoperative
stage between the en bloc and transhiatal groups or as a result
of the selection of patients with the best response to neoadju-
vant therapy for an en bloc resection. Lastly, despite the dif-
ferences between groups in regard to age and comorbidities,
we found no evidence that the neoadjuvant therapy differed
significantly between groups, with the majority of patients
receiving standard chemotherapy and radiotherapy.
In conclusion, in this study of patients with locally ad-
vanced adenocarcinoma of the esophagus, all of whom
were treated with neoadjuvant therapy, there was a significant
improvement in overall survival and survival with residual
disease in patients who had an en bloc esophagectomy com-
pared with those who had a transhiatal resection. Clearly,
even after neoadjuvant therapy, the extent of resection is an
important determinant of long-term survival from esophageal
adenocarcinoma. The explanation for this finding relates to
the higher local-regional failure rate with a transhiatal resec-
tion and likely to the removal of both known and unknown
(micrometastatic) disease with the extended lymphadenec-
tomy that is performed with the en bloc procedure. Poor sur-
vival with a transhiatal resection in patients with residual
disease mandates an en bloc resection in this group, and the
improved survival overall shouldmake an en bloc esophagec-
tomy the procedure of choice in all patients after neoadjuvant
therapy. Further improvements in survival with this deadly
disease will require chemotherapy agents and protocols that
are able to reduce the incidence of systemic recurrence and
represent a major challenge for the oncology community.
However, these compelling data proving the superiority of
the en bloc resection in patients who have had neoadjuvant
therapy should finally put to rest the question of whether an
extended resection is necessary, beneficial, or both for the
treatment of patients with adenocarcinoma of the esophagus.
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TSDiscussion
Dr Richard I. Whyte (Stanford, Calif). First, I would like to con-
gratulate Dr Rizzetto on a very interesting and well-presented paperne 2008
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TSthat really adds to our knowledge on esophageal cancer, the role of
en bloc esophagectomy, and the results of neoadjuvant therapy.
The authors are clearly presenting some very impressive results
here in terms of a 70% five-year survival in the 25% of patients who
were complete pathologic responders. That is really sort of best in
class. Also, they really demonstrate the fact that en bloc resection
results in a very low local recurrence rate.
I have 2 or 3 questions, however, and I think Dr DeMeester is
going to address those.
First, you have described candidates for neoadjuvant therapy as
having locally advanced disease proved by both endoscopic ultraso-
nographic analysis and PET scans, yet there are no data in the pre-
sentation or in the manuscript on the TNM staging of these patients.
Can you provide some information as to their pretreatment TNM
status?
Dr DeMeester. The problem with pretreatment staging is that
the clinical staging for esophageal cancer is terrible. Many of these
patients in the earlier time frame did not undergo PET scans or en-
doscopic ultrasonography. We do that routinely now, and as you
know, our preference is primary surgical resection in anyone who
we think has limited local regional disease, which for us, is patients
who had any depth of tumor with less than 5 obvious nodes deter-
mined by means of endoscopic ultrasonographic analysis or PET
scan. For anyone with 5 or more nodes, we know that the systemic
failure rate with surgical intervention alone in our experience ex-
ceeds 80%, and therefore those patients will need chemotherapy ei-
ther before or after surgical intervention. We talk to the patient about
that, and many of these patients are selected then to have preopera-
tive chemoradiotherapy, followed by surgical intervention. All of
our patients who have neoadjuvant therapy have extensive local-re-
gional disease. In fact, if you look at the final pathologic staging,
some 60% of the en bloc group had stage II or III disease after neo-
adjuvant therapy, and therefore the majority of these patients started
with significant disease.
DrWhyte. My next question sort of relates to how patients were
assigned to receive an en bloc resection or a transhiatal resection. In
the presentation we heard that there is use of the number of lymph
nodes to sort of ascribe one operation versus another. However, in
the manuscript you talk about it both being related to the age and
the presence or absence of comorbidities. I am a little confused
then as to whether you used the presence or absence of lymph nodes
or the number of lymph nodes to help determine whether patients
receive an en bloc resection or a transhiatal resection.
Dr DeMeester. I am sorry if that was confusing in the presenta-
tion. We are merely demonstrating that, as should be no surprise, en
bloc resection removes far more lymph nodes than transhiatal resec-
tion, but the number of lymph nodes has nothing to do with the se-
lection of the operation. The operation is selected on our assessment
of the patient’s physiologic ability to withstand an en bloc proce-
dure, which is a bigger deal, and therefore patients who are older
than 70 or 75 years and have any renal, cardiac, or pulmonary dys-
function are selected for a transhiatal resection. That then brings in
the concern that patients in the transhiatal group have higher comor-
bidities and are dying off as a consequence of these comorbidities
and not their cancer. We also prepared cancer-only survival statistics
and have demonstrated that the statistics and the significance be-
tween the curves are the same. In fact, all deaths, except for one
in the transhiatal group, were from cancer. Therefore the comorbid-The Journal of Thoraities are what we use to select the procedures, but that had no effect
on the outcome from the procedures.
DrWhyte. So you are not using the presence or absence of nodal
disease or the number of nodes to assign someone to en bloc versus
transhiatal resection.
Dr DeMeester. No. We use the number of nodes to determine
whether we should select patients for neoadjuvant therapy, but
that has nothing to do with whether we select them for transhiatal
or en bloc resection. Our preference is always en bloc resection,
but we will downstep to a transhiatal resection in patients who we
fear will not handle the en bloc resection based on comorbidities.
DrWhyte. My last question then is this: Why don’t you do an en
bloc resection on everyone? Your mortalities are pretty similar. In
terms of the ASA class you presented, they are roughly the same
in the transhiatal versus the en bloc resection. As for the presence
or absence of comorbidities, the numbers are fairly similar. You
had 11 of 40 patients who had significant comorbidities in your en
bloc resection group. I am thinking that persons who undergo a tran-
shiatal resection have a laparotomy, a gastric mobilization, a pretty
extensive mediastinal dissection, and then a neck incision, and the
patients undergoing en bloc resection get a bit more extensive ab-
dominal dissection and then perhaps a rather limited thoracotomy
but, in addition, a much more precise mediastinal dissection. I am
wondering why you do not do an en bloc esophagectomy in every-
one, particularly because you are clearly convinced it is the right op-
eration. Your data indicate that they have better long-term survival,
and the mortalities are somewhat similar. Why not do an en bloc re-
section on everyone? Then we can really see—sort of take out this
transhiatal versus en bloc issue—and focus on whether the potential
increased morbidity of the bigger operation is more than made up for
by the better long-term survival in these patients.
I really enjoyed the paper, and it was well presented. Thanks very
much.
Dr DeMeester. We are pretty much coming to that same conclu-
sion. Essentially everyone who comes for primary surgical resection
has an en bloc resection at this point. I have done 1 transhiatal resec-
tion maybe in the last 3 years, and that was in a guy who had a pre-
vious pneumonectomy. Therefore essentially everyone gets an en
bloc resection for primary therapy. Part of this experience now is
teaching us that even after neoadjuvant therapy, we need to push
the en bloc resection because part of our attitude initially, as I think
was present in many surgeons, was that if you had neoadjuvant ther-
apy, that was supposed to take care of the problem, and you could
probably just get by with a transhiatal resection. Therefore 5 or 10
years ago, when we were first doing this, often we would do a tran-
shiatal resection in a patient who could have had an en bloc resec-
tion, but we thought they have had neoadjuvant therapy, the
chemoradiation increases the potential morbidity particularly for
a thoracotomy, more respiratory complications, maybe it is not
worth doing that. These data now will tell us that anybody who
comes with neoadjuvant therapy at USCwill get an en bloc resection
if at all possible.
Dr Robert Cerfolio (Birmingham, Ala). Steve, excellent work. I
congratulate you and your efforts to continue to collect prospective
data on esophageal cancer. It is a lot of work, and we appreciate
everything you have contributed to the field and to our patients.
This thing about complete responders—the only way to know
who is a complete responder is to take the cancer out and look.cic and Cardiovascular Surgery c Volume 135, Number 6 1235
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Lewis esophagogastrectomy, as you do—and have shown that the
change in the maximal standardized uptake value helps predict
who will be a complete responder and who will not. When the pri-
mary tumor decreases by greater than 75%, that patient is very
likely—has a greater than 90% chance of being a complete re-
sponder. I am wondering whether you have any data that would cor-
roborate that, and then, if you do, if you would comment on the fact
that I get a lot of medical oncologists who say, ‘‘If he is a complete
responder, he does not need surgery.’’ The ones who refuse or de-
cline it because they are a ‘‘complete responder’’ all seem to return
within 9 to 12 months with bad local and often distant metastatic dis-
ease. Can you tell me how you respond to your oncologists and push
the patient to get the operation and if you havemaximal standardized
uptake value data?
Dr DeMeester. We are just starting to look at some of the max-
imal standardized uptake value data. We do not certainly have that
going back in this study population, particularly because a number
of these patients had their operations before PET scans were widely
used. I will say, though, that I am not convinced that PET scanning is
ever going to get down to the level of the cell. There is just no chance
that you are going to predict 100% of the time who has no residual
cancer. I do not think there is any test short of the pathologist with
his microscope sorting that out. The reality is, if you leave cancer
behind, the patients are going to die from their cancer. It is going
to come back. Therefore I do not see a way with any of our current
studies to rule out or to find those patients who do not need surgical
intervention because of complete pathologic response. We know
that the mucosal disease clears up first. If you cannot clear mucosal
disease with neoadjuvant therapy, then you have real problems. In
our data 60% of patients had residual disease in the esophagus,
and therefore the majority of patients do, and it should be resected
with an en bloc procedure.
Dr Cerfolio. Therefore you tell the oncologists that you do not
know whether the patients are complete responders no matter what
their repeat endoscopic ultrasonographic tests and repeat PET scans
show, and thus you, like us, recommend surgical resection.
Dr DeMeester. Repeat endoscopic ultrasonography has been
shown to be of no value after neoadjuvant therapy, and therefore I
do not even offer it. I tell the oncologists that 60% of these patients
have residual disease in the esophagus and 40% will have nodal dis-
ease, and if you read a recent article by Prenzel using immunohisto-
chemistry, 75% of patients after neoadjuvant therapy have either
histologic or immunohistochemical evidence of nodal disease.
The vast majority of these patients have disease and should have
an esophagectomy. Now the issue you brought forward is that
many oncologists have taken an approach that surgical intervention
should not be offered after neoadjuvant therapy because if you get
a complete pathologic response, your survival is pretty good, and
if you did not and you get a transhiatal resection, your survival is
horrible, and therefore why should they undergo an operation at
all after neoadjuvant therapy? That is the emphasis of this paper.
Your survival is not horrible if you do a good operation. Fifty per-
cent of patients were alive at 5 years after neoadjuvant therapy
with an en bloc resection, and even with residual disease, it was
an impressive survival. These patients should have an esophagec-
tomy, and it should be en bloc.1236 The Journal of Thoracic and Cardiovascular Surgery c JuDr Cerfolio. Our data are similar, and we agree.
Dr David Follette (Sacramento, Calif). Steven, I enjoyed your
paper, and it is one of the first to corroborate some data from East
Germany regarding complete responders and survival in squamous
cell carcinoma of the esophagus, which we do not see that much of
anymore. We really still do not know the benefit of neoadjuvant
therapy because the Walsh study is one of the only ones to show
the advantage and, as was mentioned in the talk, is severely flawed.
In my mind, what is coming to the fore is this issue of a complete
response or a partial response. We have seen good long-term sur-
vival in persons who are nonresponders to neoadjuvant therapy
with good survival rates with just definitive chemotherapy and radi-
ation therapy. My question is, you briefly mentioned to Rob that you
do not do repeat ultrasonographic analysis on these persons, but do
you use CT scanning restaging after neoadjuvant, and if they are
nonresponders or if the tumor is fed and growing with the neoadju-
vant, how do you handle that group of patients?
DrDeMeester. We definitely restage them, looking for systemic
disease. If a patient has systemic disease, we do not offer him or her
esophagectomy. If the patient does not have systemic disease, the
extent of the local regional disease does not dissuade me from mov-
ing forward. It is important to separate out squamous tumors from
adenocarcinomas. All these were adenocarcinomas. You cannot re-
ally do an en bloc resection for squamous tumors. You have milli-
meters between the trachea and major vessels, and therefore it is
a completely different disease, and for those patients, I think defin-
itive chemoradiotherapy often is an advantage. It is totally different
for a distal esophageal adenocarcinoma. Most Americans have cen-
timeters of fat between any significant structure and the esophagus,
and you can get a very excellent resection and take out the lymph
nodes, and there is no comparison between the results of good oper-
ations and definitive chemoradiotherapy in patients with distal
esophageal adenocarcinoma.
DrAlex Little (Dayton, Ohio). I have one quick follow-up ques-
tion to something that was put before. Is the difference in the oper-
ation because of the extent of the abdominal dissection or because
there was not a thoracic nodal dissection?
Dr DeMeester. It is brought out in the manuscript, but our ab-
dominal dissection is identical whether you have a transhiatal or
an en bloc resection, and therefore it is the mediastinal dissection.
As you saw, about 45% of patients had mediastinal and abdominal
nodes in the en bloc group, and therefore there is a high prevalence
of mediastinal nodes that I just do not think you can clear well, lead-
ing to the higher recurrence rate and the failure of survival in the
transhiatal group.
Dr Little. If I might, I have one quick comment to ask you to re-
act to, and it has already been alluded to. I think fully convincing
evidence will not be put before us until all comers are randomized:
to compare a relatively fit with a relatively unfit group sort of stacks
the deck ahead of time.
Dr DeMeester. That would be true if they were dying from their
comorbidities, but as I said, there was 1 death from comorbidities,
a non–cancer-related death, in the transhiatal group. All the rest of
the deaths were from cancer, and if we analyzed it based on can-
cer-related deaths only, the statistical significance is actually even
greater. In my mind the issue is closed. It is decided. The argument
is over. En bloc esophagectomy is superior to a transhiatal resection.ne 2008
